Literature DB >> 1636132

A comparison of outcome after resection for squamous cell carcinomas and adenocarcinomas of the esophagus and cardia.

S Y Law1, M Fok, S W Cheng, J Wong.   

Abstract

Among 625 patients with squamous cell carcinoma and 134 patients with adenocarcinoma of the esophagus and cardia, a one stage resection was performed upon 375 patients of the squamous carcinoma group (excluding pharyngolaryngoesophagectomy) and 92 patients in the adenocarcinoma group. The patients formed the basis of the current analysis. Male to female ratio was 7:1 for those with squamous carcinoma compared with 3.6:1.0 for those with adenocarcinoma (p = 0.037). Most squamous carcinomas were located in the middle one-third (56.3 percent) and lower one-third (33.0 percent) of the esophagus. Adenocarcinomas were predominantly found at the cardia (91.3 percent) and lower one-third (6.5 percent). Postoperatively, respiratory complications occurred in 34.4 percent of patients in the group with squamous carcinoma and in 19.6 percent of patients in the group with adenocarcinoma (p = 0.01). Cardiac complications occurred in 28.3 percent of patients in the group with squamous carcinoma and in 16.3 percent of patients in the group with adenocarcinoma (p = 0.03). Anastomotic leaks were uncommon for both groups (4.3 and 5.4 percent, respectively). Anastomotic recurrence occurred in 6.1 and 7.6 percent of patients, respectively. Respiratory complications, malignant cachexia and sepsis accounted for most of the deaths in the hospital. The 30 day mortality rates for patients with squamous carcinoma and adenocarcinoma were comparable (4.8 and 6.5 percent, respectively) (p = 0.33). After 30 days, mortality rates differed significantly (11.7 and 3.3 percent, respectively) (p = 0.026). The overall hospital mortality rates, however, were comparable (16.5 and 9.8 percent, respectively) (p = 0.14). The overall five year survival rate for both groups was 15 percent. For patients with squamous carcinomas, the five year survival rate after curative resection was 31 percent compared with 5 percent for palliative resection. For patients with adenocarcinomas, the respective five year survival rates were 35 and zero percent. It was concluded that the two types of tumor differ significantly in the incidence of postoperative morbidity, but mortality and the long term survival rates were similar.

Entities:  

Mesh:

Year:  1992        PMID: 1636132

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  14 in total

1.  Measurement of extent of spread of oesophageal squamous carcinoma by serial sectioning.

Authors:  K Y Lam; L T Ma; J Wong
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

Review 2.  Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem.

Authors:  M S Levine; J B Herman; E E Furth
Journal:  Abdom Imaging       Date:  1995 Jul-Aug

3.  Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer.

Authors:  Andrew J Walker; Bret J Spier; Scott B Perlman; Jason R Stangl; Terrence J Frick; Deepak V Gopal; Mary J Lindstrom; Tracey L Weigel; Patrick R Pfau
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

4.  microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.

Authors:  Zhao-li Chen; Xiao-hong Zhao; Ji-wen Wang; Bao-zhong Li; Zhen Wang; Jian Sun; Feng-wei Tan; Da-peng Ding; Xiao-hui Xu; Fang Zhou; Xiao-gang Tan; Jie Hang; Su-sheng Shi; Xiao-li Feng; Jie He
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

Review 5.  Preoperative chemotherapy for resectable thoracic esophageal cancer.

Authors:  Biniam Kidane; Shaun Coughlin; Kelly Vogt; Richard Malthaner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-19

6.  ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma.

Authors:  Ryota Otsuka; Yasunori Akutsu; Haruhito Sakata; Naoyuki Hanari; Kentaro Murakami; Masayuki Kano; Takeshi Toyozumi; Masahiko Takahashi; Yasunori Matsumoto; Nobufumi Sekino; Masaya Yokoyama; Koichiro Okada; Tadashi Shiraishi; Aki Komatsu; Keiko Iida; Hisahiro Matsubara
Journal:  Oncology       Date:  2017-12-08       Impact factor: 2.935

7.  Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells.

Authors:  Jian-Jun Xie; Li-Yan Xu; Jian-Yi Wu; Zhong-Ying Shen; Qing Zhao; Ze-Peng Du; Zhuo Lv; Wei Gu; Feng Pan; Xiu-E Xu; Dong Xie; En-Min Li
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

8.  Risk analysis in resection of squamous cell carcinoma of the esophagus.

Authors:  S Y Law; M Fok; J Wong
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

9.  Operable esophageal carcinoma: current results from Hong Kong.

Authors:  M Fok; S Y Law; J Wong
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

10.  Morbidity and mortality after esophagectomy for esophageal carcinoma: a risk analysis.

Authors:  Ines Gockel; Christoph Exner; Theodor Junginger
Journal:  World J Surg Oncol       Date:  2005-06-21       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.